Vaccine of hepatitis B has no conclusion Chongqing beer " It is blind to take off" Have not been " made known "

Vaccine of hepatitis B has no conclusion Chongqing beer " It is blind to take off" Have not been " made known "
Probational reporter sub the intersection of fur coat and the intersection of sea and bright the intersection of Chongqing and the intersection of beer and the intersection of hepatitis B and the intersection of vaccine and the intersection of �� stage and clinical research, editor of boat, take off blind announcement of fruiting in today appearance summer, after three degrees are postponed revealing, this share proves that has not provided the conclusion yet. November 24, Chongqing beer reveal hold relevant to take off blind meeting on November 27, on December 5 the intersection of announcement and relevant information of can take off blind working, until the fact that today, company does not release the intersection of research and progress and announcement of resumption of trading. Chongqing beer is in the clinical research of �� stage of vaccine of hepatitis B " The progress situation " China explains to point out, the main curative effect index of this clinical validity assessment is in order to follow up a case by regular visits to to the 76th week, HBeAg happens / resist the proportion of patient that HBe serum changes. The more key one " The preliminary statistics of the main curative effect index " In proving, the company claims, its CRO (clinical contract study organization) that engages RPS medical the science and technology ' Beijing) The company is carrying on overall statistical analysis to the clinical data now; This research enters 360 cases of group together, among them 331 finish studying in 76 weeks. Check through expert's blind attitude, it is 360 altogether to include in the safe data collection, 354 include in the purpose and analyze the collection, 328 include in according with the scheme collection; Accord with the relevant requirement of national Bureau of Drugs Supervision " standardard management of clinical trial of medicines ". The above-mentioned explanation continues pointing out, according to " the project counts the progress of analytical work to prove" which RPS Company submitted, carry on HbeAg turn overcast to resist HBe, transfer serum of male genital to, change statistics analytical work of replying rate at the same time 76 week at the research already at present, the result reveals tentatively: The replying rate of placebo group is 28.2%; The treatment is used ' Synthetic peptide) Vaccine group 600�� g replying rate of hepatitis B is 30.0%; The treatment is used ' Synthetic peptide) Vaccine group 900�� g replying rate of hepatitis B is 29.1%. The beer respect in Chongqing is not to the above-mentioned data drawing a conclusion judgement. In today announcement, Chongqing beer shows, RPS Company, to every curative effect of this research (including virus and serum index) And the overall statistical analysis of security index is in progress; Meanwhile, " the project counts the progress of analytical work to prove" that RPS Company submits thinks, after counting the analysis report and finishing and forming the final report of clinical research, can judge, treat, spend synthetically ' Synthetic peptide) Hepatitis B vaccine curative effect and security in this research. Chongqing beer claims finally, after RPS Company offers and counts the end draft of analysis report, and then reveal the relevant information of this clinical research project in time. The hepatitis B vaccine concept of Chongqing beer starts to enter a clinical research in 2003 in October of 1998, and apply for the clinical research of �� stage in April of 2008. Author: Probational reporter Xia ZiHang

|